SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?


To: GST who wrote (160019)3/31/2004 12:52:38 PM
From: SI Dave  Read Replies (1) | Respond to of 164684
 
>>...but are the incentives for performance the same?

It's all relative. The basic incentive for performance is supposed to be continuation of employment, benefits, pay raises, and opportunities for advancement. Incentives should be a "tip" for performance. All too often, the value of incentives granted are way out of line with job performance and reasonable compensation. The base pay should be appropriate to the position, with annual raises if performance meets or beats expectations of shareholders and the BOD. It's ridiculous to see the shareholders give away their equity as incentives that are often valued at many times the executive's salary.



To: GST who wrote (160019)5/23/2004 8:33:23 AM
From: Madharry  Read Replies (2) | Respond to of 164684
 
Out of the market options are not worthless at all- many of the biotech companies repriced those options at what was almost the a multiyear low for many of the companies. Sepracor for example went down from 60+ to 4 the options were repriced in the 6 area. It would be interesting for someone to sit down and caluculate the cost of option repricing to shareholders, and by the way in most cases this repricing is not subject to shareholder approval.